

10-9-2022

## Pichia pastoris, a promising microbial cell factory for continuous manufacturing

Xavier Garcia-Ortega

*Universitat Autònoma de Barcelona, Spain, Xavier.garcia@uab.cat*

José Luis Montesinos-Seguí

*Universitat Autònoma de Barcelona, Spain*

Francisco Valero

*Universitat Autònoma de Barcelona, Spain*

Follow this and additional works at: [https://dc.engconfintl.org/biomanufact\\_v](https://dc.engconfintl.org/biomanufact_v)

---

### Recommended Citation

Xavier Garcia-Ortega, José Luis Montesinos-Seguí, and Francisco Valero, "Pichia pastoris, a promising microbial cell factory for continuous manufacturing" in "Integrated Continuous Biomanufacturing V", Ana Azevedo, Técnico Lisboa, Portugal; Jason Walther, Sanofi, USA; Rohini Deshpande, Amgen, USA Eds, ECI Symposium Series, (2022). [https://dc.engconfintl.org/biomanufact\\_v/48](https://dc.engconfintl.org/biomanufact_v/48)

This Abstract and Presentation is brought to you for free and open access by the Proceedings at ECI Digital Archives. It has been accepted for inclusion in Integrated Continuous Biomanufacturing V by an authorized administrator of ECI Digital Archives. For more information, please contact [franco@bepress.com](mailto:franco@bepress.com).



# *Pichia pastoris*, a promising microbial cell factory for continuous biomanufacturing

Xavier Garcia-Ortega, José Luis Montesinos-Seguí, Francisco Valero


Department of Chemical, Biological and Environmental Engineering, School of Engineering, Universitat Autònoma de Barcelona, 08193 Bellaterra (Barcelona), Spain.

Xavier.garcia@uab.cat

## Introduction

- Pichia pastoris* (*Komagataella phaffii*), microbial cell factory for **recombinant protein production (RPP)** and **metabolites**
- As yeast combines:
  - Cheap and fast** processes
  - Eukaryotic **folding capacity** and ability to perform **post-translational modifications**
- Capacity to grow up to **high cell density** in mineral media
- Wide **toolbox of genetic tools** including **Crispr**
- Strong promoters** with different regulations that allows to reach **high production yields**
- Low hyperglycosylation** native patterns
- Strains with **Humanized glycosylation**
- Secretion** of native proteins at low levels
- Target proteins secreted to the broth with high purity**

## Second preferred option for recombinant microbial expression



- Reported secreted titers up to 25 g/L**
- Reported secreted protein purity in the supernatant up to 98%**

## Biomanufactured *Pichia*-based products in the market


- Widely used RPP platform, **over 5000 recombinant proteins successfully expressed**
- Numerous products in the market**, usually produced in fed-batch

### FDA/EMA approved biopharmaceuticals

#### Enzyme-based products



#### Nanobodies-based products (single-domain antibodies)





### Other relevant industrial sectors

**Cell culture:** Trypsin and growth factors  
**Organic acids:** Building blocks for biopolymers  
**Biopolymers:** Collagen  
**Cosmetics:** Spider silk protein  
**Industrial enzymes:** Lipases  
**Feed:** Phytases

### FDA approved animal-free food products

- Meat
- Milk
- Eggs




## Continuous technology in *Pichia* bioprocesses

### 1. Powerful tool for systems biology

- Non-Dynamic systems, **steady state conditions**
- Highly **reliable and robust** cultivations
- Suitable to study the effect of a single parameter (pH, T, growth rate,)


### Systems biology requires high quality representative samples

- Homogeneous cell population
- Constant cell metabolic state



### Strong tool for strain and bioprocess development

- Rational Strain Design**
- Rational Bioprocess Development**



### 2. Industrial implementation of continuous biomanufacturing


Advantages of continuous for biomanufacturing:

- ✓ Increased efficiency (productivity and economy)
- ✓ Time and cost reduction for new drugs development
- ✓ Space saving, lower capital and maintenance costs
- ✓ Enhanced bioprocess robustness and product quality and safety
- ✓ Environmental impact reduction

- FDA encourages the transition towards continuous processes** to improve the bioprocess robustness and product quality



- The **reduced cost of goods** offered by the continuous processes is essential to assure the economic viability of products not targeted to the pharma industry



*Pichia*-based products



IMPOSSIBLE



Motif BeefWorks™

motif

### Advantages of *P. pastoris* towards continuous process implementation

- High strain stability:** Expression cassettes integrated in *P. pastoris* genome increases strain stability, avoiding eventual losses of episomal plasmids
- Low contamination risk:** Specially with methanol-based processes
- Long experience** of the *Pichia* community with different continuous strategies:
  - Chemostat (Nutrient limited below  $\mu_{max}$ )
  - Turbidostat (Non nutrient limited)
  - Retentostat (Nutrient limited below  $\mu_{max}$ )
- Capacity to scale-up** *Pichia*-based bioprocesses up to 100 m<sup>3</sup>

### Acknowledgements:

This was funded by the Project PID 2019-104666GB-I00 of the Spanish Ministry of Science and Innovation. This technology will be further developed during Christian Doppler Foundation-funded project entitled "CD-Lab for Innovative *Pichia pastoris* host and vector systems" developed in partnership between UAB and TU Graz.